Navigation Links
Sorrento Therapeutics Receives Frost & Sullivan's Prestigious 2013 Global Investment Opportunity Award in the Oncology Market
Date:6/6/2013

MOUNTAIN VIEW, Calif., June 6, 2013 /PRNewswire/ -- Based on its recent analysis of the oncology market, Frost & Sullivan recognizes Sorrento Therapeutics, Inc. (OTCBB: SRNE); (Sorrento) with the 2013 Global Frost & Sullivan Investment Opportunity Award. In a pharmaceutical industry that is crowded with early stage competitors aiming to develop monoclonal antibodies (mAbs) or other novel therapeutics in oncology, Sorrento believes it has gained an edge through a combination of factors, including its diverse mAb library, experienced management team, and superior ability to select and rapidly develop promising drug targets, such as fully human anti-PD-L1 and anti-PD-1 mAbs.

One of Sorrento's key differentiators is its robust intellectual property (IP). Its extensive patent portfolio, which positions it to develop next-generation targeted therapeutics and nanomedicines, includes issued patents and filed patent applications for its lead product candidate Cynviloq™, G-MAB® library, its human G-MAB®-derived mAbs and TOCOSOL®-PAC, as well as groundbreaking platform technologies such as antibody formulated drug conjugates (AfDC) and recombinant intravenous immunoglobulin (rIVIG). Sorrento, through its pending acquisition of IGDRASOL, Inc. has obtained the exclusive marketing and distribution rights to Cynviloq™ in the United States and the 27 EU member countries. Cynviloq™ is patent protected worldwide by Samyang Biopharmaceutical Corporation, a South Korean corporation, until 2028, preventing competitors from using similar processes to create competitive therapeutics.

Cynviloq™ has pharmacokinetic (PK) properties amenable to personalized dosing, allowing for an improved therapeutic index when compared to industry leader Abraxane®, which is marketed by Celgene Corporation. Sorrento plans to exploit Cynviloq™ po
'/>"/>

SOURCE Frost & Sullivan
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sorrento Therapeutics Awarded Third Phase I STTR Grant
2. Sorrento Therapeutics Signs Exclusive Option to Acquire IGDRASOL
3. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
4. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
5. Sorrento Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference in New York City
6. Sorrento Therapeutics Receives Frost & Sullivans 2013 Global Investment Opportunity Award in Oncology
7. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
8. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
9. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
10. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
11. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... ORLANDO, Fla. , Sept. 19, 2014 /PRNewswire/ ... to grow, with the publication of two papers this ... Otolaryngology – Head and Neck Surgery , ... both objective and subjective measures of sleep disordered breathing, ... for the reduction in obstructive sleep apnea severity and ...
(Date:9/19/2014)... 2014  CytRx Corporation (Nasdaq: CYTR ), ... today announced that David J. Haen , Vice ... in the Biotech Industry Conference on Friday, September 26 th ... take place at the Millennium Broadway Hotel in ... live and archived webcast of the presentation will be ...
(Date:9/18/2014)... , September 19, 2014 ... ( http://www.researchandmarkets.com/research/qqjrnh/global_molecular ) has announced the addition ... 2014-2018" report to their offering. ... involves the study of chromosomes using molecular ... of genes and chromosomes. It plays a ...
Breaking Medicine Technology:New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 4CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 3Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 2Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 3
... SAN RAMON, Calif., Aug. 20 HRI, a San Francisco ... leading the way in helping California healthcare employers comply with ... effect August 5th. , , California is ... from exposure to infectious airborne diseases, including the H1N1 flu. ...
... TITUSVILLE, N.J., Aug. 21 The U.S. Food and ... the New Drug Application (NDA) for carisbamate, an anti-epileptic ... , The NDA, filed in October 2008 ... (J&JPRD) on behalf of Ortho-McNeil-Janssen Pharmaceuticals, Inc. seeks approval ...
Cached Medicine Technology:San Ramon HR Firm Leads Response to New Cal/OSHA ATD Law 2FDA Issues Complete Response Letter for Carisbamate 2FDA Issues Complete Response Letter for Carisbamate 3
(Date:9/21/2014)... 2014 Originally approved by the ... Flovent (fluticasone propionate) is a synthetic ICS therapy ... the maintenance treatment of asthma prophylactically in children ... formulations, Diskus and HFA, which received the FDA ... ingredient, fluticasone propionate, can bind to glucocorticoid receptors ...
(Date:9/21/2014)... 2014 An experienced review website in ... hosting ranking list and announced that FatCow ( http://www.top10bestseohosting.com/go/FatCow.com/ ... suppliers. , There has been a boom in ... resulted in an increase in the number of web ... at very affordable prices. VPS (Virtual Private Server) is ...
(Date:9/21/2014)... C8 lawsuits move forward in the U.S. District ... 20 possible C8 lawsuits selected for bellwether trials ... & Schulte LLC. Court records show these six C8 ... filed that represent individuals who purportedly developed kidney cancer, ... being exposed to water contaminated by the C8 chemical ...
(Date:9/20/2014)... Vegas, NV (PRWEB) September 21, 2014 ... by Dr. Kenneth Pullman that is helping thousands of ... their diabetes symptoms without shots, pills, or prescriptions has ... review. , “There are currently tens of millions ... both Type 1 and Type 2 diabetes, and unfortunately, ...
(Date:9/20/2014)... Islands of Loreto, Baja, Mexico (PRWEB) September 20, 2014 ... of Loreto today announced the resort did not experience ... fully operational, with all amenities and activities available. , ... September 14, 2014, bringing intense wind, rain and powerful ... Baja Peninsula, Villa del Palmar Islands of Loreto experienced ...
Breaking Medicine News(10 mins):Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4Health News:Top10BestSEOHosting.com: FatCow, GoDaddy And Bluehost Are The Best VPS Hosting Suppliers 2Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 2Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 3Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 4Health News:Diabetes Protocol: Review Exposes Kenneth Pullman’s Breakthrough Discovery About Diabetes Management 2Health News:Villa del Palmar at the Islands of Loreto Fully Functioning After Hurricane 2Health News:Villa del Palmar at the Islands of Loreto Fully Functioning After Hurricane 3
... following Congress, failure,to override SCHIP veto, WASHINGTON, Oct. ... Fattah:, "It,s a sad day when America,s children ... for and look after their most basic needs. It,s,a ... defend its most,vulnerable citizens., "The failure of the ...
... Must Happen Before Congressional Thanksgiving Break on State,Children,s ... "Congress cannot go home,to its Thanksgiving break ... of mind for America,s laboring families by passing ... Delgado, President and CEO of the,National Alliance for ...
... the Northern California Cancer Center, the University of Southern ... found that increased exposure to sunlight which increases ... decrease the risk of advanced breast cancer. , In ... Journal of Epidemiology, the researchers found that women with ...
... 2007 Research will be reported at TCT 2007, ... (CRF), that demonstrates that early intervention saves lives in ... pain. , Responding to media reports of recent studies ... to men, Dr. Alexandra J. Lansky, MD, Director of ...
... half of sufferers are kept awake by a variety of ... Along with typical symptoms such as acid reflux, the less ... coughing, choking, wheezing, choking, snoring, sore throat, and chest pain ... new U.S. survey. , The poll of 701 GERD patients ...
... Oct. 18 Following is a statement from ... the House,s failure to,override President Bush,s veto of ... of the Congressional Democrats and,some courageous Republicans to ... health care to children whose parents cannot,afford it. ...
Cached Medicine News:Health News:Exposure to sunlight may decrease risk of advanced breast cancer by half 2Health News:Exposure to sunlight may decrease risk of advanced breast cancer by half 3Health News:Are women at greater risk from angioplasty? 2
Wire lid retractor, may be clamped to surgical drape with suture or elastic band. Small pair....
Flexible rake retractor, 3 blunt prongs....
Bayonet dressing forceps serrated jaws...
Medpor Encophthalmos Wedge mimics the contour of the orbital floor and provides volume to restore the orbit to its normal shape and size....
Medicine Products: